Molecular dynamics simulations reveal multiple pathways of ligand dissociation from thyroid hormone receptors.
暂无分享,去创建一个
Leandro Martínez | Igor Polikarpov | Paul Webb | Munir S Skaf | L. Martínez | J. Baxter | P. Webb | I. Polikarpov | M. Skaf | Milton T Sonoda | John D Baxter | M. T. Sonoda
[1] Q. Gibson,et al. Mapping the Pathways for O2 Entry Into and Exit from Myoglobin* , 2001, The Journal of Biological Chemistry.
[2] Thomas S. Scanlan,et al. Design of thyroid hormone receptor antagonists from first principles , 2002, The Journal of Steroid Biochemistry and Molecular Biology.
[3] K. Schulten,et al. Unbinding of retinoic acid from its receptor studied by steered molecular dynamics. , 1999, Biophysical journal.
[4] Johan Auwerx,et al. Nuclear receptors and the control of metabolism. , 2003, Annual review of physiology.
[5] M. Brunori,et al. Cavities and packing defects in the structural dynamics of myoglobin , 2001, EMBO reports.
[6] R. Fletterick,et al. Two RTH Mutants with Impaired Hormone Binding , 2003 .
[7] Peter A. Kollman,et al. Molecular mechanics simulation of protein-ligand interactions: binding of thyroid hormone analogs to prealbumin , 1982 .
[8] R G Smith,et al. Ligand-induced stabilization of PPARgamma monitored by NMR spectroscopy: implications for nuclear receptor activation. , 2000, Journal of molecular biology.
[9] D. Moore,et al. Dynamic stabilization of nuclear receptor ligand binding domains by hormone or corepressor binding. , 2000, Molecular cell.
[10] Paul Webb,et al. Thyroxine-Thyroid Hormone Receptor Interactions* , 2004, Journal of Biological Chemistry.
[11] B. Katzenellenbogen,et al. Coactivator peptides have a differential stabilizing effect on the binding of estrogens and antiestrogens with the estrogen receptor. , 1999, Molecular endocrinology.
[12] K. O'reilly,et al. A subtype-selective thyromimetic designed to bind a mutant thyroid hormone receptor implicated in resistance to thyroid hormone. , 2001, Journal of the American Chemical Society.
[13] Paul Webb,et al. Selective activation of thyroid hormone signaling pathways by GC-1: a new approach to controlling cholesterol and body weight , 2004, Trends in Endocrinology & Metabolism.
[14] R Elber,et al. Distal pocket residues affect picosecond ligand recombination in myoglobin. An experimental and molecular dynamics study of position 29 mutants. , 1992, The Journal of biological chemistry.
[15] R J Fletterick,et al. Nuclear-receptor ligands and ligand-binding domains. , 1999, Annual review of biochemistry.
[16] M. Bowman,et al. A chemical, genetic, and structural analysis of the nuclear bile acid receptor FXR. , 2003, Molecular cell.
[17] R. Fletterick,et al. Structure-based design and synthesis of a thyroid hormone receptor (TR) antagonist. , 2002, Endocrinology.
[18] Mary E. McGrath,et al. A structural role for hormone in the thyroid hormone receptor , 1995, Nature.
[19] R. Fletterick,et al. Thyroid hormone receptor-beta mutations conferring hormone resistance and reduced corepressor release exhibit decreased stability in the N-terminal ligand-binding domain. , 2003, Molecular endocrinology.
[20] Zbigniew Dauter,et al. Molecular basis of agonism and antagonism in the oestrogen receptor , 1997, Nature.
[21] J. Katzenellenbogen,et al. Probing conformational changes in the estrogen receptor: evidence for a partially unfolded intermediate facilitating ligand binding and release. , 2001, Molecular endocrinology.
[22] Vincent Laudet,et al. Principles for modulation of the nuclear receptor superfamily , 2004, Nature Reviews Drug Discovery.
[23] J. Baxter,et al. Effects of the thyroid hormone receptor agonist GC-1 on metabolic rate and cholesterol in rats and primates: selective actions relative to 3,5,3'-triiodo-L-thyronine. , 2004, Endocrinology.
[24] H. Gronemeyer,et al. Nuclear receptor ligand-binding domains: three-dimensional structures, molecular interactions and pharmacological implications. , 2000, Trends in pharmacological sciences.
[25] T. Willson,et al. Crystal Structure of the Glucocorticoid Receptor Ligand Binding Domain Reveals a Novel Mode of Receptor Dimerization and Coactivator Recognition , 2002, Cell.
[26] Michael L. Quillin,et al. Structural and functional effects of apolar mutations of the distal valine in myoglobin. , 1995, Journal of molecular biology.
[27] P. Chambon,et al. Crystal structure of the human RXRα ligand‐binding domain bound to its natural ligand: 9‐cis retinoic acid , 2000 .
[28] T. Willson,et al. Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-γ , 1998, Nature.
[29] P. Kraulis. A program to produce both detailed and schematic plots of protein structures , 1991 .
[30] Koh Jt,et al. A subtype-selective thyromimetic designed to bind a mutant thyroid hormone receptor implicated in resistance to thyroid hormone. , 2001 .
[31] K. Schulten,et al. Energetics of glycerol conduction through aquaglyceroporin GlpF , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[32] Kendall W Nettles,et al. Ligand control of coregulator recruitment to nuclear receptors. , 2005, Annual review of physiology.
[33] J D Baxter,et al. The nuclear hormone receptor gene superfamily. , 1995, Annual review of medicine.
[34] K Schulten,et al. VMD: visual molecular dynamics. , 1996, Journal of molecular graphics.
[35] E A Merritt,et al. Raster3D: photorealistic molecular graphics. , 1997, Methods in enzymology.
[36] J. Fetrow. Omega loops; nonregular secondary structures significant in protein function and stability , 1995, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[37] R. Fletterick,et al. MOLECULAR AND STRUCTURAL BIOLOGY OF THYROID HORMONE RECEPTORS , 1998, Clinical and experimental pharmacology & physiology. Supplement.
[38] M. Karplus,et al. Enhanced sampling in molecular dynamics: use of the time-dependent Hartree approximation for a simulation of carbon monoxide diffusion through myoglobin , 1990 .
[39] Paul Webb,et al. Selective modulation of thyroid hormone receptor action , 2001, The Journal of Steroid Biochemistry and Molecular Biology.
[40] Jean-Paul Renaud,et al. Crystal structure of the RAR-γ ligand-binding domain bound to all-trans retinoic acid , 1995, Nature.
[41] Jonathan Greer,et al. The Three-dimensional Structures of Antagonistic and Agonistic Forms of the Glucocorticoid Receptor Ligand-binding Domain , 2003, Journal of Biological Chemistry.
[42] P. Chambon,et al. Crystal structure of the human RXRalpha ligand-binding domain bound to its natural ligand: 9-cis retinoic acid. , 2000, The EMBO journal.
[43] Grazia Chiellini,et al. Ligand selectivity by seeking hydrophobicity in thyroid hormone receptor , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[44] David A. Agard,et al. The Structural Basis of Estrogen Receptor/Coactivator Recognition and the Antagonism of This Interaction by Tamoxifen , 1998, Cell.
[45] C. Glass,et al. The coregulator exchange in transcriptional functions of nuclear receptors. , 2000, Genes & development.
[46] P. Webb. Selective activators of thyroid hormone receptors , 2004, Expert opinion on investigational drugs.
[47] L. Ye,et al. Thyroid receptor ligands. 1. Agonist ligands selective for the thyroid receptor beta1. , 2003, Journal of medicinal chemistry.
[48] R. Elber,et al. Application of the locally enhanced sampling (LES) and a mean field with a binary collision correction (cLES) to the simulation of Ar diffusion and NO recombination in myoglobin , 1994 .
[49] J. Baxter,et al. Rational design and synthesis of a novel thyroid hormone antagonist that blocks coactivator recruitment. , 2002, Journal of medicinal chemistry.
[50] John E. Straub,et al. ENERGY EQUIPARTITIONING IN THE CLASSICAL TIME-DEPENDENT HARTREE APPROXIMATION , 1991 .
[51] K E Carlson,et al. Altered ligand binding properties and enhanced stability of a constitutively active estrogen receptor: evidence that an open pocket conformation is required for ligand interaction. , 1997, Biochemistry.
[52] Jorge Nocedal,et al. On the limited memory BFGS method for large scale optimization , 1989, Math. Program..
[53] J. Schwabe,et al. A dynamic mechanism of nuclear receptor activation and its perturbation in a human disease , 2003, Nature Structural Biology.
[54] L. Moore,et al. 2.1 A crystal structure of human PXR in complex with the St. John's wort compound hyperforin. , 2003, Biochemistry.
[55] L. Verlet. Computer "Experiments" on Classical Fluids. I. Thermodynamical Properties of Lennard-Jones Molecules , 1967 .
[56] M Karplus,et al. Retinoic acid receptor: a simulation analysis of retinoic acid binding and the resulting conformational changes. , 1999, Journal of molecular biology.
[57] R J Fletterick,et al. Hormone selectivity in thyroid hormone receptors. , 2001, Molecular endocrinology.
[58] R J Fletterick,et al. Structure and specificity of nuclear receptor-coactivator interactions. , 1998, Genes & development.
[59] W. L. Jorgensen,et al. Development and Testing of the OPLS All-Atom Force Field on Conformational Energetics and Properties of Organic Liquids , 1996 .
[60] L. Martínez,et al. A review on the dynamics of water , 2004 .
[61] R. Fletterick,et al. Two resistance to thyroid hormone mutants with impaired hormone binding. , 2003, Molecular endocrinology.
[62] Johan Malm,et al. Selective thyroid hormone receptor-β activation: A strategy for reduction of weight, cholesterol, and lipoprotein (a) with reduced cardiovascular liability , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[63] R. Friesner,et al. Evaluation and Reparametrization of the OPLS-AA Force Field for Proteins via Comparison with Accurate Quantum Chemical Calculations on Peptides† , 2001 .
[64] Ron Elber,et al. The thermal equilibrium aspects of the time dependent Hartree and the locally enhanced sampling approximations: Formal properties, a correction, and computational examples for rare gas clusters , 1993 .
[65] Howard M. Einspahr,et al. Crystallographic structures of the ligand-binding domains of the androgen receptor and its T877A mutant complexed with the natural agonist dihydrotestosterone , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[66] Y. Uratani. Immunoaffinity purification and reconstitution of sodium-coupled branched-chain amino acid carrier of Pseudomonas aeruginosa. , 1992, The Journal of biological chemistry.